MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Use with caution

Zopiclone 7.5mg tablets (Sigma Pharmaceuticals Plc)

Explore other Zopiclone formulations Explore other Zopiclone 7.5mg tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

This compatibility recommendation is derived from Zimovane 7.5mg tablets (Sanofi) and Zopiclone 7.5mg tablets (Accord Healthcare Ltd).

Use with caution

Zopiclone 7.5mg tablets (Teva UK Ltd)

Explore other Zopiclone formulations Explore other Zopiclone 7.5mg tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

This compatibility recommendation is derived from Zimovane 7.5mg tablets (Sanofi) and Zopiclone 7.5mg tablets (Accord Healthcare Ltd).

Incompatible

Zoton FasTab 15mg (Pfizer Ltd)

Explore other Lansoprazole formulations Explore other Lansoprazole 15mg orodispersible tablets suppliers

Stability Notes

Highly sensitive to moisture, so unsuitable for inclusion in MCA.

Provenance

This compatibility recommendation is derived from Zoton FasTab 15mg (Pfizer Ltd).

Incompatible

Zoton FasTab 30mg (Pfizer Ltd)

Explore other Lansoprazole formulations Explore other Lansoprazole 30mg orodispersible tablets suppliers

Stability Notes

Highly sensitive to moisture, so unsuitable for inclusion in MCA.

Provenance

This compatibility recommendation is derived from Zoton FasTab 30mg (Pfizer Ltd).

Incompatible

Zovirax 200mg dispersible tablets (GlaxoSmithKline UK Ltd)

Explore other Aciclovir formulations Explore other Aciclovir 200mg dispersible tablets suppliers

Stability Notes

Formulation not suitable for use in MCAs. No stability data in MCAs available.

Provenance

This recommendation is based on the products Aciclovir 200mg dispersible tablets (Crescent Pharma Ltd).

Incompatible

Zovirax 200mg dispersible tablets (Sigma Pharmaceuticals Plc)

Explore other Aciclovir formulations Explore other Aciclovir 200mg dispersible tablets suppliers

Stability Notes

Formulation not suitable for use in MCAs. No stability data in MCAs available.

Provenance

This recommendation is based on the products Aciclovir 200mg dispersible tablets (Crescent Pharma Ltd).

Incompatible

Zovirax 800mg dispersible tablets (Sigma Pharmaceuticals Plc)

Explore other Aciclovir formulations Explore other Aciclovir 800mg dispersible tablets suppliers

Stability Notes

Formulation not suitable for use in MCAs. No stability data in MCAs available.

Provenance

This recommendation is based on the products Aciclovir 800mg dispersible tablets (Crescent Pharma Ltd).

No Stability Information

Zubsolv 1.4mg/0.36mg sublingual tablets (Accord-UK Ltd)

Explore other Buprenorphine + Naloxone formulations Explore other Buprenorphine 1.4mg / Naloxone 360microgram sublingual tablets sugar free suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zubsolv 11.4mg/2.9mg sublingual tablets (Accord-UK Ltd)

Explore other Buprenorphine + Naloxone formulations Explore other Buprenorphine 11.4mg / Naloxone 2.9mg sublingual tablets sugar free suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zubsolv 2.9mg/0.71mg sublingual tablets (Accord-UK Ltd)

Explore other Buprenorphine + Naloxone formulations Explore other Buprenorphine 2.9mg / Naloxone 710microgram sublingual tablets sugar free suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zubsolv 5.7mg/1.4mg sublingual tablets (Accord-UK Ltd)

Explore other Buprenorphine + Naloxone formulations Explore other Buprenorphine 5.7mg / Naloxone 1.4mg sublingual tablets sugar free suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zubsolv 8.6mg/2.1mg sublingual tablets (Accord-UK Ltd)

Explore other Buprenorphine + Naloxone formulations Explore other Buprenorphine 8.6mg / Naloxone 2.1mg sublingual tablets sugar free suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zumenon 1mg tablets (Exeltis UK Ltd)

Explore other Estradiol formulations Explore other Estradiol 1mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zumenon 1mg tablets (Lexon (UK) Ltd)

Explore other Estradiol formulations Explore other Estradiol 1mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Zumenon 1mg tablets (Necessity Supplies Ltd)

Explore other Estradiol formulations Explore other Estradiol 1mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

Print this list

Compatible

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Use with caution

There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Incompatible

Medicines under this category are not suitable for use in MCAs.

No Stability Information

These medicines have not been reviewed by SPS.